Universal Beteiligungs und Servicegesellschaft mbH Cuts Stock Holdings in ADMA Biologics Inc $ADMA

Universal Beteiligungs und Servicegesellschaft mbH reduced its stake in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 80.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 48,925 shares of the biotechnology company’s stock after selling 196,326 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in ADMA Biologics were worth $717,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Royal Bank of Canada raised its position in shares of ADMA Biologics by 112.7% in the 1st quarter. Royal Bank of Canada now owns 95,885 shares of the biotechnology company’s stock worth $1,903,000 after acquiring an additional 50,801 shares in the last quarter. Ashton Thomas Private Wealth LLC purchased a new stake in ADMA Biologics in the first quarter valued at $217,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of ADMA Biologics by 59.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 816,590 shares of the biotechnology company’s stock valued at $16,201,000 after buying an additional 305,064 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of ADMA Biologics by 16.6% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 9,222 shares of the biotechnology company’s stock valued at $168,000 after purchasing an additional 1,312 shares in the last quarter. Finally, Ameritas Advisory Services LLC purchased a new position in ADMA Biologics during the second quarter worth approximately $46,000. Hedge funds and other institutional investors own 75.68% of the company’s stock.

ADMA Biologics Stock Performance

Shares of NASDAQ ADMA opened at $17.30 on Monday. The company has a quick ratio of 3.65, a current ratio of 7.13 and a debt-to-equity ratio of 0.18. The firm’s 50-day moving average price is $18.57 and its two-hundred day moving average price is $17.03. ADMA Biologics Inc has a 52-week low of $13.50 and a 52-week high of $25.67. The stock has a market capitalization of $4.12 billion, a P/E ratio of 20.12 and a beta of 0.47.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings data on Wednesday, November 5th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.16. ADMA Biologics had a return on equity of 36.52% and a net margin of 42.87%.The business had revenue of $134.22 million during the quarter, compared to analyst estimates of $131.20 million. During the same quarter in the previous year, the firm posted $0.15 EPS. The business’s revenue for the quarter was up 12.0% compared to the same quarter last year. As a group, sell-side analysts forecast that ADMA Biologics Inc will post 0.51 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “hold (c)” rating on shares of ADMA Biologics in a report on Tuesday, December 23rd. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $28.50.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.